most essential to guard against variation in local standards of collecting data. With this taken care of, it then becomes necessary to programme adequately for computer. We seem to be moving into an era when magnetic discs will be used for recording data and cases will be up-dated daily through a telephone system, thereby enabling ready retrieval of data for sampling or administrative purposes. It should be appreciated here that one is talking of 'hardware' data: age, sex, occupation, education, ethnic origin, and so on -which may be analysed in terms of diagnosis -and not in terms of clinical studies which would require special programming and would not be incorporated in a case register.
Norway has had a national register of all patients admitted to psychiatric hospitals for many years which Odegaard has used to good advantage epidemiologically. A few State registers have been instituted in U.S.A. with, so far, limited success. The aims and methods of one U.K. register in a municipal area, the Camberwell Cumulative Psychiatric Case Register has recently been described (Social Psychiatry, 3, 116), especially its value as a samplingframe and for planning new facilities. The Aberdeen register in U.K. is also well-known. The importance of such a facility to mental health services is that, for those conditions where the administrative prevalence is near the 'community prevalence', the accumulation of cases can lead to the determination of risk dates. In some cases, this would need to be supplemented through data obtained from other resources known to exist in the area. Where there is a well-defined population, census data can be used and all case registers should operate on this basis. Confidentiality, of course, i s essential.
EDITORIAL ANNOTATIONS

MONOAMIN ES AND AFFECTIVE DISORDERS
A fundamental approach to the understanding of affective disorders is provided by the hypothesis that these are due to alterations in brain monoamines. Certainly, many of the drugs that are of value in the treatment of affective disorders influence the storage, release, metabolism or action of the pharmacologically active monoamines that are present in the brain. The main monoamines are noradrenaline, 5-hydroxytryptamine (or serotonin) and dopamine. It has been suggested by Brodie and his colleagues1 that noradrenaline is the modulator of synaptic transmission in a diencephalic system concerned with energy expenditure and the alert state, whereas 5-hydroxytryptamine acts similarly in a diencephalic system controlling energy conservation and sleep. Dopamine, which is largely concentrated in the corpus striatum, is also implicated in affective changes. If the absolute or relative concentrations of these amines are altered by drugs, changes in affective state are noticeable.
At the present time, most research is being concentrated on the role of noradrenaline in the central nervous system as a determinant of mood and behaviour. Noradrenaline in pre-synaptic nerve terminals is stored in granules in a bound form from which it is released by nerve impulses. The released noradrenaline is available for action on post-synaptic receptors and thereby influences the activity of the post-synaptic neurone. The free noradrenaline may be metabolized extracellularly by catechol-0-methyltransferase, or it may be taken up again into pre synaptic terminals. Monoamine oxidase, an enzyme which catalyses the oxidative deamination of noradrenaline, is present in mitochondria of adrenergic neurones and it acts on free noradrenaline in the axoplasm. Noradrenaline which is bound into the storage granules after being taken up is not attacked by monoamine oxidase.
Drugs can alter the amount of noradrenaline that is available for action on the post-synaptic receptor in various ways. Reserpine weakens the binding of noradrenaline in the storage granules so that it is released slowly into the axoplasm where it is inactivated by monoamine oxidase. The stores of noradrenaline are thereby gradually depleted and less is available for mediating the action of the nerve impulse. This effect of reserpine explains the impairment of peripheral adrenergic function that it produces. The concept that the changes in mood and behaviour produced by reserpine were due to a similar impairment of central adrenergic function followed from observations that there was a higher incidence of depression in patients on reserpine than in those on other antihypertensive agents. Reserpine causes sedation, blepharospasm, hypothermia, diarrhoea, salivation and muscular rigidity in animals and in human subjects. These effects are also produced by tetrabenazine, another drug which depletes central stores of noradrenaline. The changes in behaviour and in autonomic function produced by reserpine are reversed by the administration d phenylalanine or dopa: these substances are amino acid precursors of noradrenaline and they cause restoration of the content of noradrenaline in the brain. The content of noradrenaline in peripheral and central adrenergic neurones is also reduced by methyldopa (Aldomet), but its mechanism of action differs from that of reserpine. There are a number of reports that methyldopa produces depression as a sideeffect of its antihypertensive action, but it does so to a lesser extent than reserpine (Bunney and Daviso).
Inhibition of monoamine oxidase prevents the destruction of free intra-neuronal noradrenaline, so that more noradrenaline becomes available for release. Work with monoamine oxidase inhibitors was first stimulated by the observation that iproniazid had an antidepressant effect in patients being given the drug for the treatment of tuberculosis, and that it affected the metabolism of monoamines. This led to the synthesis of other monoamine oxidase inhibitors which were also effective antidepressant agents.
The combination of observations with reserpine and monoamine oxidase inhibitors suggested the hypothesis that a decrease in the level of functional noradrenaline resulted in depression whereas an increase in the level resulted in effective treatment of depression and even stimulation.
The tricyclic antidepressants, imipramine, amitriptyline and their desmethyl derivatives, at first did not appear to fit into this scheme since they do not release noradrenaline, nor do they inhibit monoamine oxidase. However they do affect adrenergic mechanisms by impairing reuptake noradrenaline.
This process is responsible for the inactivation of more than 90% of released noradrenaline. When it is blocked, the amount of noradrenaline avaitable to the receptor is increased and it acts for a longer time. Stimulant drugs such as cocaine, methylphenidate and amphetamine also block the reuptake of noradrenaline. Amphetamine has the additional action of releasing noradrenaline from the stores. These observations are in accord with the hypothesis than an increase in the amount of noradrenaline available for action results in an antidepressant action or causes excitement. States of over-excitement have been reported in patients in whom a monoamine oxidase inhibitor and a tricyclic antidepressant are used in conjunction or immediately following each othera. The depression produced by reserpine or tetrabenazine is prevented or reversed by anti-depressant drugs, suggesting a balance of opposing effects on adrenergic mechanisms.
The success of the hypothesis that changes in mood and behaviour produced by depressant and antidepressant drugs are due to changes in the availability of noradrenaline led to the suggestion that this substance is normally a determinant of mental state. Schildkraut4 has summarised the hypothesis as follows ". . . some if not all depressions are associated with an absolute or relative deficiency of catecholamines, particularly norepinephrine (noradrenaline), at functionally important adrenergic receptor sites in the brain. Elation conversely may be associated with an excess of such amines."
However noradrenaline is not the only brain monoamine that may be concerned in affective states: 5-hydroxytryptamine is also strongly implicated. It is found in the same areas of the brain as noradrenaline, chiefly the hypothalamus, and also occurs in such areas as the limbic system which contains little noradrenaline. Like noradrenaline, it is stored in nerve endings and is a substrate for monoamine oxidase. Reserpine depletes stores of 5-hydroxytryptamine whereas monoamine oxidase inhibitors cause an increase in its content in brain and other tissues. Treatment with tryptophan (a precursor of 5-hydroxytryptamine) in conjunction with monoamine oxidase inhibitors has been found to elevate mood. Furthermore, imipramine and similar compounds block the uptake of 5-hydroxytryptamine into tissuess, although it has not yet been established that this has the same physiological significance as it does with the catecholamines. These findings suggest a correlation between the availability of 5-hydroxytryptamine and affective state. They amount to the same sort of evidence for the hypothesis that changes in affective state may be caused by changes in the availability of noradrenaline. It is not clear whether noradrenaline acts separately or in conjunction with 5-hydroxytryptamine to affect central nervous function.
Studies on the urinary excretion of monoamines and their metabolites are sometimes used to deduce the relationship between monoamines and affective states. However this is unjustified and may be misleading since the substances appearing in the urine reflect changes in the body as a whole and not just in the brain. Moreover, urinary levels of noradrenaline and normetanephrine, the product formed from noradrenaline by catechol-0-methyltransferase, are in very small part derived from brain metabolism as the blood-brain barrier is not permeable to hydroxylated amines. Schildkraut? and his associates found that urinary levels of normetanephrine were increased in patients with mania or cyclic manicdepressive psychosis and were also increased in patients in whom imipramine was an effective antidepressant whereas urinary levels of vanillylmandelic acid ( V M A ) were decreased. Normetanephrine is regarded as the breakdown product of noradrenaline which is thought to reflect chiefly extracellular metabolism whereas V M A levels reflect intracellular deamination. The fact that imipramine blocks the reuptake of noradrenaline is in accord with these findings. However the source of the noradrenaline could be from autonomic adrenergic neurones rather than from the central nervous system. In this case, the observations would have more relevance to sideeffects than to the desired effect of imipramine.
The metabolism of indoleamines in depression has been studied by Coppen and his associates6. They found that urinary excretion of tryptamine and its metabolic product indoleacetic acid was decreased during depression and increased upon recovery with treatment. Here, as in studies with catecholamine metabolites, interpretation is difficult for similar reasons, namely that urinary changes may not reflect brain changes especially as indoleamines and their metabolites are not freely transported across the blood-brain barrier.
While much of this evidence for the role of biogenic amines seems to fit into a satisfactory pattern, Dewhurst has criticized the methodology of the clinical and laboratory studies*. He put forward an alternative theory of cerebral amine action based on studies of the behavioural effects of sixty amines and related compounds in various species and proposed that amines can be divided according to their cerebral actions into two distinct and opposing categories: type A (excitant) and type C (depressant). The determinant of type of action is lipid solubility, type A amines (substituted ethylamines) being both lipophilic and hydrophilic, and type C amines (substituted ethanolamines) being hydrophilic only. Other variations in the chemical structure affect potency and duration of action but not type of action. Naturally occurring amines of type A are tryptamine and B-phenylethylamine. The excitant action of type A amines is specifically antagonized by methysergide, and this drug is reported to be of use in the treatment of manian. Naturally occurring type C amines are noradrenaline and adrenaline. S-hydroxytryptamine has a biphasic (excitant then depressant) action and is classed as type B. Dewhurst's conclusions have obvious points of difference from the catecholamine theory, but he is examining the role of monoarnines in cerebral function from a different standpoint. No doubt his views will gain stronger support if encouraging clinical and experimental correlations are found. 
CLINICAL RESEARCH IN DEPRESSION
In principle there are two approaches to studying the nature of depressive illness. On the one hand, therapeutic developments have generated fruitful heuristic theories such as the catecholamine theory of depression. The opposite tack is to examine homogeneous groups of patients with appropriate controls, in an attempt to identify the physiological characteristics of depression and from these to infer its pathogenesis.
We need not expect the results of these two approaches to be obviously related and complementary. In general medicine, for example, the actions of digoxin at the cellular level tell us something about the impaired contractile state of cardiac failure, but this pharmacological information does not indicate the possible pathogenesis of hypertension or valvular disease which preceded the onset of cardiac failure.
Theories of depressive illness based only on pharmacological data seem to share this difficulty; in fact their emphasis on single factors may be misleading for there is no more reason to suppose that all depressive states have a common pathogenesis than there is to suppose that cardiac failure has a single cause.
A dysfunction of central adrenergic neurones may be the final expression of several pathogenetic mechanisms but the frequency of resistance and recurrence with antidepressant treatment indicates that their action is only at the end point of a process. To continue the analogy, not all patients in cardiac failure respond to or remain controlled on digoxin alone.
